In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.
Author: FWA
In patients with obesity and knee osteoarthritis, once-weekly semaglutide (2.4 mg) significantly reduced body weight and pain compared to placebo, though it was associated with gastrointestinal side effects.
In adults with type 2 diabetes inadequately controlled with metformin (alone or with sulfonylurea), oral semaglutide (7 mg and 14 mg) significantly reduced HbA1c and body weight compared to sitagliptin over 26 weeks, while the 3 mg dose showed no significant benefit.
In patients with inadequately controlled type 2 diabetes on SGLT-2 inhibitors, adding semaglutide significantly improved HbA1c and reduced body weight compared to placebo, though it was associated with an increased frequency of gastrointestinal side effects.
In patients with type 2 diabetes at high cardiovascular (CV) risk, oral semaglutide demonstrated non-inferior cardiovascular safety to placebo, showing no significant increase in major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
In adults with obesity (BMI ≥30 kg/m²), daily subcutaneous semaglutide significantly promoted weight loss compared to liraglutide and placebo, with gastrointestinal symptoms as the main side effect.
In patients with type 2 diabetes inadequately managed on diet and exercise (with or without metformin), daily subcutaneous semaglutide significantly improved glycaemic control and promoted weight loss compared to both liraglutide and placebo, though it was associated with higher gastrointestinal side effects.
In patients with type 2 diabetes on basal insulin, adding semaglutide significantly improved glycaemic control (HbA1c reduction) and weight loss compared to placebo, though it was associated with more gastrointestinal side effects.
In patients with type 2 diabetes, weekly subcutaneous semaglutide significantly reduced HbA1c and body weight compared to dulaglutide at similar doses, though it was associated with higher gastrointestinal side effects.
In patients with type 2 diabetes, oral semaglutide significantly improved HbA1c levels and reduced body weight compared to placebo over 26 weeks, showing comparable efficacy to subcutaneous semaglutide, though associated with mild-to-moderate gastrointestinal side effects.